Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE), a Delaware corporation, filed this Current Report on Form 8-K on August 12, 2026. The filing announces financial results and operational updates for the three and six months ended June 30, 2026. The company also updated its corporate presentation slide deck on the same date.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) containing the detailed financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text. The filing text does not provide a clear value for any specific financial metric.
Material Changes
The filing indicates that the company issued a press release detailing results for the period ended June 30, 2026. However, the text of the 8-K itself does not quantify material changes versus prior periods or describe specific operational shifts beyond the issuance of the update.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, and specific risk factors are contained within the attached press release and corporate presentation, which are incorporated by reference but not reproduced in the main body of this filing. The filing explicitly states that the information in Item 2.02 and its exhibits is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the quarter and half-year ended June 30, 2026.
- Examine Exhibit 99.2 (Corporate Presentation) for updated clinical trial timelines, pipeline milestones, and capital requirements.
- Verify the company's cash runway and any recent financing activities mentioned in the press release.
- Confirm the status of any regulatory filings or clinical data readouts referenced in the operational update.